Combination regimens involving SETD2 inhibitors with WEE1 inhibitors, HDMIs, or PARPis have demonstrated encouraging therapeutic efficacy in preclinical cancer models and are expected to form the basis for new treatment strategies for prostate cancer. This evidence concerns the gene WEE1 and prostate carcinoma.